Download PDF
Semin Respir Crit Care Med 2009; 30(5): 539-546
DOI: 10.1055/s-0029-1238912
© Thieme Medical Publishers

Atypical Mycobacterial and Fungal Infections in Cystic Fibrosis

Laurie A. Whittaker1 , Charlotte Teneback1
  • 1Division of Pulmonary and Critical Care Medicine, University of Vermont College of Medicine, Burlington, Vermont
Further Information

Publication History

Publication Date:
16 September 2009 (online)

    Permissions and Reprints

ABSTRACT

Nontuberculous mycobacteria (NTM) and fungi are prevalent in the sputum of cystic fibrosis patients and are increasingly recognized to cause clinically significant disease. In both instances the organisms are ubiquitous within the environment making exposure common, although specific risk factors that contribute to active pulmonary infection have not been identified. A consistent and aggressive approach to screening for NTM and fungi within the cystic fibrosis airway is likely indicated, especially in the setting of clinical deterioration despite standard antipseudomonal therapies.

KEYWORDS

Cystic fibrosis - nontuberculous mycobacteria - fungi - lung disease

REFERENCES

  • 1 Rowe S M, Miller S, Sorscher E J. Cystic fibrosis.  N Engl J Med. 2005;  352 1992-2001
    CrossrefPubMedGoogle Scholar
  • 2 Wolinsky E. Nontuberculous mycobacteria and associated diseases.  Am Rev Respir Dis. 1979;  119 107-159
    PubMedGoogle Scholar
  • 3 Guay D R. Nontuberculous mycobacterial infections.  Ann Pharmacother. 1996;  30 819-830
    PubMedGoogle Scholar
  • 4 Olivier K N, Weber D J, Wallace Jr R J Nontuberculous Mycobacteria in Cystic Fibrosis Study Group et al. Nontuberculous mycobacteria, I: Multicenter prevalence study in cystic fibrosis. [see comment].  Am J Respir Crit Care Med. 2003;  167 828-834
    CrossrefPubMedGoogle Scholar
  • 5 Olivier K N, Yankaskas J R, Knowles M R. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis.  Semin Respir Infect. 1996;  11 272-284
    PubMedGoogle Scholar
  • 6 Sexton P, Harrison A C. Susceptibility to nontuberculous mycobacterial lung disease.  Eur Respir J. 2008;  31 1322-1333
    CrossrefPubMedGoogle Scholar
  • 7 Fowler S J, French J, Screaton N J et al.. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics.  Eur Respir J. 2006;  28 1204-1210
    CrossrefPubMedGoogle Scholar
  • 8 Torrens J K, Dawkins P, Conway S P, Moya E. Non-tuberculous mycobacteria in cystic fibrosis.  Thorax. 1998;  53 182-185
    CrossrefPubMedGoogle Scholar
  • 9 Chalermskulrat W, Sood N, Neuringer I P et al.. Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.  Thorax. 2006;  61 507-513
    CrossrefPubMedGoogle Scholar
  • 10 Griffith D E, Aksamit T, Brown-Elliott B A et al.. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.  Am J Respir Crit Care Med. 2007;  175 367-416
    CrossrefPubMedGoogle Scholar
  • 11 Kent P, Kubica G. Public health mycobacteriology: a guide for the level III laboratory. In: Services UDoHaH, ed. Centers for Disease Control and Prevention. 1985
    PubMedGoogle Scholar
  • 12 Whittier S, Hopfer R L, Knowles M R, Gilligan P H. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis.  J Clin Microbiol. 1993;  31 861-864
    PubMedGoogle Scholar
  • 13 Whittier S, Olivier K, Gilligan P, Knowles M, Della-Latta P. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group . Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients.  J Clin Microbiol. 1997;  35 2706-2708
    PubMedGoogle Scholar
  • 14 Bange F C, Kirschner P, Böttger E C. Recovery of mycobacteria from patients with cystic fibrosis.  J Clin Microbiol. 1999;  37 3761-3763
    PubMedGoogle Scholar
  • 15 Coelho A G, Zamarioli L A, Reis C M, Nascimento A C, Rodrigues J dosS. Gene probes versus classical methods in the identification of mycobacteria.  J Bras Pneumol. 2008;  34 922-926
    PubMedGoogle Scholar
  • 16 Peter-Getzlaff S, Lüthy J, Böddinghaus B, Böttger E C, Springer B. Development and evaluation of a molecular assay for detection of nontuberculous mycobacteria by use of the cobas amplicor platform.  J Clin Microbiol. 2008;  46 4023-4028
    CrossrefPubMedGoogle Scholar
  • 17 Gilljam M, Berning S E, Peloquin C A, Strandvik B, Larsson L O. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease.  Eur Respir J. 1999;  14 347-351
    PubMedGoogle Scholar
  • 18 Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium-complex lung disease.  Am J Respir Crit Care Med. 1995;  152 1094-1096
    PubMedGoogle Scholar
  • 19 Colsky A S, Hanly A, Elgart G, Kerdel F A. Treatment of refractory disseminated Mycobacterium abscessus infection with interferon gamma therapy.  Arch Dermatol. 1999;  135 125-127
    CrossrefPubMedGoogle Scholar
  • 20 Condos R, Rom W N, Schluger N W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.  Lancet. 1997;  349 1513-1515
    CrossrefPubMedGoogle Scholar
  • 21 Moss R B, Mayer-Hamblett N, Wagener J et al.. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.  Pediatr Pulmonol. 2005;  39 209-218
    CrossrefPubMedGoogle Scholar
  • 22 Camargos P, Le Bourgeois M, Revillon Y et al.. Lung resection in cystic fibrosis: a survival analysis.  Pediatr Pulmonol. 2008;  43 72-76
    CrossrefPubMedGoogle Scholar
  • 23 Häusler M, Franke E, Wendt G, Kentrup H, Döhmen H, Kusenbach G. Pneumonectomy in cystic fibrosis.  Pediatr Pulmonol. 1999;  28 376-379
    CrossrefPubMedGoogle Scholar
  • 24 Smith M B, Hardin Jr W D, Dressel D A, Beckerman R C, Moynihan P C. Predicting outcome following pulmonary resection in cystic fibrosis patients.  J Pediatr Surg. 1991;  26 655-659
    CrossrefPubMedGoogle Scholar
  • 25 Forslöw U, Geborek A, Hjelte L, Petrini B, Heurlin N. Early chemotherapy for non-tuberculous mycobacterial infections in patients with cystic fibrosis.  Acta Paediatr. 2003;  92 910-915
    CrossrefPubMedGoogle Scholar
  • 26 Olivier K N, Weber D J, Lee J H Nontuberculous Mycobacteria in Cystic Fibrosis Study Group et al. Nontuberculous mycobacteria, II: Nested-cohort study of impact on cystic fibrosis lung disease. [see comment].  Am J Respir Crit Care Med. 2003;  167 835-840
    CrossrefPubMedGoogle Scholar
  • 27 Bartz R R, Love R B, Leverson G E, Will L R, Welter D L, Meyer K C. Pre-transplant mechanical ventilation and outcome in patients with cystic fibrosis.  J Heart Lung Transplant. 2003;  22 433-438
    CrossrefPubMedGoogle Scholar
  • 28 Sanguinetti M, Ardito F, Fiscarelli E et al.. Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis.  J Clin Microbiol. 2001;  39 816-819
    CrossrefPubMedGoogle Scholar
  • 29 Taylor J L, Palmer S M. Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient.  J Heart Lung Transplant. 2006;  25 985-988
    CrossrefPubMedGoogle Scholar
  • 30 Flume P A, Egan T M, Paradowski L J, Detterbeck F C, Thompson J T, Yankaskas J R. Infectious complications of lung transplantation: impact of cystic fibrosis.  Am J Respir Crit Care Med. 1994;  149 1601-1607
    CrossrefPubMedGoogle Scholar
  • 31 Navarro J, Rainisio M, Harms H K et al.. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis.  Eur Respir J. 2001;  18 298-305
    CrossrefPubMedGoogle Scholar
  • 32 Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis.  Br Med Bull. 2009;  89 93-110
    PubMedGoogle Scholar
  • 33 Bakare N, Rickerts V, Bargon J, Just-Nübling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis.  Mycoses. 2003;  46 19-23
    CrossrefPubMedGoogle Scholar
  • 34 Stevens D A, Moss R B, Kurup V P Participants in the Cystic Fibrosis Foundation Consensus Conference et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis—state of the art: Cystic Fibrosis Foundation Consensus Conference.  Clin Infect Dis. 2003;  37(Suppl 3) S225-S264
    CrossrefPubMedGoogle Scholar
  • 35 Nelson L A, Callerame M L, Schwartz R H. Aspergillosis and atopy in cystic fibrosis.  Am Rev Respir Dis. 1979;  120 863-873
    PubMedGoogle Scholar
  • 36 Cimon B, Carrère J, Vinatier J F, Chazalette J P, Chabasse D, Bouchara J P. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis.  Eur J Clin Microbiol Infect Dis. 2000;  19 53-56
    CrossrefPubMedGoogle Scholar
  • 37 Vázquez-Tsuji O, Campos Rivera T, Rondán Zárate A, Mirabal García M. Endobronchitis by Scedosporium apiospermum in a child with cystic fibrosis.  Rev Iberoam Micol. 2006;  23 245-248
    CrossrefPubMedGoogle Scholar
  • 38 Horre R, Schaal K P, Siekmeier R, Sterzik B, de Hoog G S, Schnitzler N. Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study.  Respiration. 2004;  71 360-366
    CrossrefPubMedGoogle Scholar
  • 39 Kusenbach G, Skopnik H, Haase G, Friedrichs F, Döhmen H. Exophiala dermatitidis pneumonia in cystic fibrosis.  Eur J Pediatr. 1992;  151 344-346
    CrossrefPubMedGoogle Scholar
  • 40 Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis.  Scand J Infect Dis. 2001;  33 777-779
    CrossrefPubMedGoogle Scholar
  • 41 Shoseyov D, Brownlee K G, Conway S P, Kerem E. Aspergillus bronchitis in cystic fibrosis.  Chest. 2006;  130 222-226
    CrossrefPubMedGoogle Scholar
  • 42 Rüping M J, Vehreschild J J, Cornely O A. Patients at high risk of invasive fungal infections: when and how to treat.  Drugs. 2008;  68 1941-1962
    CrossrefPubMedGoogle Scholar
  • 43 Burns J L, Van Dalfsen J M, Shawar R M et al.. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.  J Infect Dis. 1999;  179 1190-1196
    CrossrefPubMedGoogle Scholar
  • 44 Hogan D A, Kolter R. Pseudomonas–Candida interactions: an ecological role for virulence factors.  Science. 2002;  296 2229-2232
    CrossrefPubMedGoogle Scholar
  • 45 Agarwal R, Nath A, Aggarwal A N, Gupta D, Chakrabarti A. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India.  Mycoses. 2009 Jan 24;  , [Epub ahead of print]
    PubMedGoogle Scholar
  • 46 Denning D W, O’Driscoll B R, Powell G et al.. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study.  Am J Respir Crit Care Med. 2009;  179 11-18
    CrossrefPubMedGoogle Scholar
  • 47 Máiz L, Cuevas M, Quirce S et al.. Serologic IgE immune responses against Aspergillus fumigatus and Candida albicans in patients with cystic fibrosis.  Chest. 2002;  121 782-788
    CrossrefPubMedGoogle Scholar
  • 48 Hartl D, Latzin P, Zissel G, Krane M, Krauss-Etschmann S, Griese M. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.  Am J Respir Crit Care Med. 2006;  173 1370-1376
    CrossrefPubMedGoogle Scholar
  • 49 Travis L B, Roberts G D, Wilson W R. Clinical significance of Pseudallescheria boydii: a review of 10 years’ experience.  Mayo Clin Proc. 1985;  60 531-537
    PubMedGoogle Scholar
  • 50 Tadros T S, Workowski K A, Siegel R J, Hunter S, Schwartz D A. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): an emerging mycosis.  Hum Pathol. 1998;  29 1266-1272
    CrossrefPubMedGoogle Scholar
  • 51 Guignard S, Hubert D, Dupont B et al.. Multifocal Scedosporium apiospermum spondylitis in a cystic fibrosis patient.  J Cyst Fibros. 2008;  7 89-91
    CrossrefPubMedGoogle Scholar
  • 52 Symoens F, Knoop C, Schrooyen M et al.. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation.  J Heart Lung Transplant. 2006;  25 603-607
    CrossrefPubMedGoogle Scholar
  • 53 Haase G, Skopnik H, Groten T, Kusenbach G, Posselt H G. Long-term fungal cultures from sputum of patients with cystic fibrosis.  Mycoses. 1991;  34 373-376
    PubMedGoogle Scholar
  • 54 Haase G, Skopnik H, Kusenbach G. Exophiala dermatitidis infection in cystic fibrosis.  Lancet. 1990;  336 188-189
    PubMedGoogle Scholar
  • 55 Lipp H P. Antifungal agents—clinical pharmacokinetics and drug interactions.  Mycoses. 2008;  51(Suppl 1) 7-18
    CrossrefPubMedGoogle Scholar
  • 56 Herbrecht R, Denning D W, Patterson T F Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 408-415
    CrossrefPubMedGoogle Scholar
  • 57 Walsh T J, Anaissie E J, Denning D W Infectious Diseases Society of America et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.  Clin Infect Dis. 2008;  46 327-360
    CrossrefPubMedGoogle Scholar
  • 58 Wark P, Wilson A W, Gibson P G. Azoles for allergic bronchopulmonary aspergillosis associated with asthma.  Cochrane Database Syst Rev. 2001;  (4) CD001108 , Review. Update in: Cochrane Database Syst Rev 2003;(3):CD001108
    PubMedGoogle Scholar
  • 59 Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.  Clin Infect Dis. 2007;  45 1610-1617
    CrossrefPubMedGoogle Scholar
  • 60 Fisher B T, Zaoutis T E. Treatment of invasive candidiasis in immunocompromised pediatric patients.  Paediatr Drugs. 2008;  10 281-298
    CrossrefPubMedGoogle Scholar
  • 61 Kauffman C A, Carver P L. Update on echinocandin antifungals.  Semin Respir Crit Care Med. 2008;  29 211-219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Marr K A, Boeckh M, Carter R A, Kim H W, Corey L. Combination antifungal therapy for invasive aspergillosis.  Clin Infect Dis. 2004;  39 797-802
    CrossrefPubMedGoogle Scholar
  • 63 Patterson T F, Boucher H W, Herbrecht R European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG) et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.  Clin Infect Dis. 2005;  41 1448-1452
    CrossrefPubMedGoogle Scholar
  • 64 Lass-Flörl C, Mayr A, Perkhofer S et al.. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.  Antimicrob Agents Chemother. 2008;  52 3637-3641
    CrossrefPubMedGoogle Scholar

Laurie A WhittakerM.D. 

Division of Pulmonary and Critical Care Medicine, University of Vermont College of Medicine

149 Beaumont Ave., Burlington, VT 05405

Email: laurie.whittaker@uvm.edu

      >